A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers

PURPOSE: To compare pharmacokinetics, safety, tolerability, and immunogenicity between SB8, a bevacizumab biosimilar, and the European Union (EU) and United States (US) reference products (bevacizumab-EU, bevacizumab-US). METHODS: In this randomized, double-blind, parallel-group, and single-dose stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Donghoon, Lee, Yoon Jung, Choi, Jihye, Lee, Dahyoung, Park, Minjeong, Petkova, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515939/
https://www.ncbi.nlm.nih.gov/pubmed/32949267
http://dx.doi.org/10.1007/s00280-020-04144-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515939/
https://www.ncbi.nlm.nih.gov/pubmed/32949267
http://dx.doi.org/10.1007/s00280-020-04144-7

Ejemplares similares